Sipuleucel-T: Prototype for development of anti-tumor vaccines

Estrella Carballido, Mayer Fishman

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Prostate cancer immunotherapy officially debuted with the recent FDA approval of Sipuleucel-T. The novel trend of cancer immunotherapy relies on the identification of particular tumor-associated antigens, like prostatic acid phosphatase (PAP). Sipuleucel-T consists of autologous dendritic cells activated in vitro with recombinant fusion protein PA2024, PAP-linked to granulocyte-macrophage colony-stimulating factor. Sipuleucel-T represents a prototype for the development of cancer vaccines. Preclinical and clinical data as well as landmark studies for the existing narrow chemotherapy alternatives and early immunotherapy trials will be discussed. The pivotal trial demonstrated a 4.1-month difference of median survival, but with no effect on time to progression in asymptomatic or minimally symptomatic metastatic castrate-resistant patients. Several immunologic effects were observed in the treated population, including antibody and T cell-specific activity to P2024 and PAP. With all new therapies the extent of clinical and objective benefits versus encountered limitations should be evaluated. This review highlights the events and decisions in the process of the development of Sipuleucel-T. We discuss how this successful immunotherapy outcome challenges us to use it as a starting point for variations to or try to amplify practical anticancer progress within the antitumor vaccine paradigm.

Original languageEnglish (US)
Pages (from-to)112-119
Number of pages8
JournalCurrent Oncology Reports
Volume13
Issue number2
DOIs
StatePublished - Apr 2011
Externally publishedYes

Fingerprint

Cancer Vaccines
Immunotherapy
Recombinant Fusion Proteins
Neoplasm Antigens
Granulocyte-Macrophage Colony-Stimulating Factor
Dendritic Cells
Prostatic Neoplasms
Vaccines
T-Lymphocytes
Drug Therapy
Survival
sipuleucel-T
Antibodies
Population
prostatic acid phosphatase
Neoplasms
Therapeutics

Keywords

  • Dendritic cell vaccine
  • Immunotherapy
  • PAP-GM-CSF fusion protein
  • Prostate cancer
  • Vaccines

ASJC Scopus subject areas

  • Oncology

Cite this

Sipuleucel-T : Prototype for development of anti-tumor vaccines. / Carballido, Estrella; Fishman, Mayer.

In: Current Oncology Reports, Vol. 13, No. 2, 04.2011, p. 112-119.

Research output: Contribution to journalArticle

Carballido, Estrella ; Fishman, Mayer. / Sipuleucel-T : Prototype for development of anti-tumor vaccines. In: Current Oncology Reports. 2011 ; Vol. 13, No. 2. pp. 112-119.
@article{1fc30b2ee7894cf78661eae9bd65f357,
title = "Sipuleucel-T: Prototype for development of anti-tumor vaccines",
abstract = "Prostate cancer immunotherapy officially debuted with the recent FDA approval of Sipuleucel-T. The novel trend of cancer immunotherapy relies on the identification of particular tumor-associated antigens, like prostatic acid phosphatase (PAP). Sipuleucel-T consists of autologous dendritic cells activated in vitro with recombinant fusion protein PA2024, PAP-linked to granulocyte-macrophage colony-stimulating factor. Sipuleucel-T represents a prototype for the development of cancer vaccines. Preclinical and clinical data as well as landmark studies for the existing narrow chemotherapy alternatives and early immunotherapy trials will be discussed. The pivotal trial demonstrated a 4.1-month difference of median survival, but with no effect on time to progression in asymptomatic or minimally symptomatic metastatic castrate-resistant patients. Several immunologic effects were observed in the treated population, including antibody and T cell-specific activity to P2024 and PAP. With all new therapies the extent of clinical and objective benefits versus encountered limitations should be evaluated. This review highlights the events and decisions in the process of the development of Sipuleucel-T. We discuss how this successful immunotherapy outcome challenges us to use it as a starting point for variations to or try to amplify practical anticancer progress within the antitumor vaccine paradigm.",
keywords = "Dendritic cell vaccine, Immunotherapy, PAP-GM-CSF fusion protein, Prostate cancer, Vaccines",
author = "Estrella Carballido and Mayer Fishman",
year = "2011",
month = "4",
doi = "10.1007/s11912-011-0152-5",
language = "English (US)",
volume = "13",
pages = "112--119",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "2",

}

TY - JOUR

T1 - Sipuleucel-T

T2 - Prototype for development of anti-tumor vaccines

AU - Carballido, Estrella

AU - Fishman, Mayer

PY - 2011/4

Y1 - 2011/4

N2 - Prostate cancer immunotherapy officially debuted with the recent FDA approval of Sipuleucel-T. The novel trend of cancer immunotherapy relies on the identification of particular tumor-associated antigens, like prostatic acid phosphatase (PAP). Sipuleucel-T consists of autologous dendritic cells activated in vitro with recombinant fusion protein PA2024, PAP-linked to granulocyte-macrophage colony-stimulating factor. Sipuleucel-T represents a prototype for the development of cancer vaccines. Preclinical and clinical data as well as landmark studies for the existing narrow chemotherapy alternatives and early immunotherapy trials will be discussed. The pivotal trial demonstrated a 4.1-month difference of median survival, but with no effect on time to progression in asymptomatic or minimally symptomatic metastatic castrate-resistant patients. Several immunologic effects were observed in the treated population, including antibody and T cell-specific activity to P2024 and PAP. With all new therapies the extent of clinical and objective benefits versus encountered limitations should be evaluated. This review highlights the events and decisions in the process of the development of Sipuleucel-T. We discuss how this successful immunotherapy outcome challenges us to use it as a starting point for variations to or try to amplify practical anticancer progress within the antitumor vaccine paradigm.

AB - Prostate cancer immunotherapy officially debuted with the recent FDA approval of Sipuleucel-T. The novel trend of cancer immunotherapy relies on the identification of particular tumor-associated antigens, like prostatic acid phosphatase (PAP). Sipuleucel-T consists of autologous dendritic cells activated in vitro with recombinant fusion protein PA2024, PAP-linked to granulocyte-macrophage colony-stimulating factor. Sipuleucel-T represents a prototype for the development of cancer vaccines. Preclinical and clinical data as well as landmark studies for the existing narrow chemotherapy alternatives and early immunotherapy trials will be discussed. The pivotal trial demonstrated a 4.1-month difference of median survival, but with no effect on time to progression in asymptomatic or minimally symptomatic metastatic castrate-resistant patients. Several immunologic effects were observed in the treated population, including antibody and T cell-specific activity to P2024 and PAP. With all new therapies the extent of clinical and objective benefits versus encountered limitations should be evaluated. This review highlights the events and decisions in the process of the development of Sipuleucel-T. We discuss how this successful immunotherapy outcome challenges us to use it as a starting point for variations to or try to amplify practical anticancer progress within the antitumor vaccine paradigm.

KW - Dendritic cell vaccine

KW - Immunotherapy

KW - PAP-GM-CSF fusion protein

KW - Prostate cancer

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=79955814192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955814192&partnerID=8YFLogxK

U2 - 10.1007/s11912-011-0152-5

DO - 10.1007/s11912-011-0152-5

M3 - Article

C2 - 21243538

AN - SCOPUS:79955814192

VL - 13

SP - 112

EP - 119

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 2

ER -